High MCM10 expression mediates TMZ resistance and promotes the progression of glioma
Cancer Chemotherapy and Pharmacology · 2025
DOI: 10.1007/s00280-025-04807-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2025. Verfasst von Qiusi Tian und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, 3201 Hospital of Xi'an Jiaotong University Health Science Center, Hanzhong, 723001, China. Hauptthemen laut MEDLINE: Temozolomide, Drug Resistance, Neoplasm, Glioma, Minichromosome Maintenance Proteins. Die Arbeit nennt 37 Literaturangaben. Gefördert von: Natural Science Foundation of Shaanxi Province, Key Project of General Medical Research.
Abstract (Originalsprache)
BACKGROUND: In glioblastoma, the heterogeneity of tumors often complicates treatment outcomes, particularly resistance to temozolomide (TMZ). This study aimed to investigate the expression characteristics of MCM10 in gliomas and its potential role in TMZ resistance. METHODS: Analyze the expression of MCM10 in glioma cells within the datasets Glioma_GSE102130, Glioma_GSE130224, Glioma_GSE131928_10X, and Glioma_GSE131928_Smartseq2 using the TISCH2 single-cell database.Subsequently, the expression level of MCM10 was evaluated using the TMZ-resistant cell lines U251-TR and LN229-TR. Glioma cells with reduced MCM10 expression were constructed through lentiviral interference.Construct glioma cells with MCM10 knockdown through lentiviral interference. Additionally, this study conducts an association analysis between MCM10 expression and patterns of DNA methylation and RNA methylation.Finally, the function of MCM10 was validated in a heterotopic mouse model. RESULTS: MCM10 mRNA is highly expressed in osteoclast-like malignant cells (OC-likemalignant cells) and oligodendrocyte progenitor-like malignant cells (OPC-like malignant cells). After treatment with TMZ, the levels of MCM10 protein and mRNA significantly increased. Knocking down MCM10 significantly reduced the migration and invasion of U251 and LN229 cells, while altering the expression of molecular markers associated with epithelial-mesenchymal transition (EMT). Weighted gene co-expression network analysis (WGCNA) revealed signaling pathways associated with drug resistance and identified overlapping differentially expressed mRNAs between resistant cells and MCM10 knockdown cells. High expression of MCM10 is associated with low DNA methylation, and MCM10 methylation is positively correlated with patient survival rates. Furthermore, inhibition of MCM10 significantly slowed tumor growth, indicating its potential as a therapeutic target for gliomas. CONCLUSION: MCM 10 is a key mediator of TMZ resistance in glioblastoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, 3201 Hospital of Xi'an Jiaotong University Health Science Center, Hanzhong, 723001, China.
- The Second Clinical School, Nanchang University, No. 999 Xuefu Avenue, Honggutan District, Nanchang, 330038, China.
- The Laboratory of Cell Biochemistry and Topogenetic Regulation, College of Bioengineering and Faculty of Medical Sciences, Chongqing University, No. 174 Shazheng Street, Shapingba District, Chongqing, 400044, China. bjz…
Förderung
- Natural Science Foundation of Shaanxi Province
- Key Project of General Medical Research
Zitieren
APA
Tian, Q., Bao, Z., Zhao, Y., & Zhang, Q. (2025). High MCM10 expression mediates TMZ resistance and promotes the progression of glioma. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-025-04807-3
Vancouver
Tian Q, Bao Z, Zhao Y, Zhang Q. High MCM10 expression mediates TMZ resistance and promotes the progression of glioma. Cancer Chemotherapy and Pharmacology. 2025. doi:10.1007/s00280-025-04807-3
BibTeX
@article{Tian2025,
author = {Tian, Qiusi and Bao, Zhijun and Zhao, Yifei and Zhang, Qun},
title = {High MCM10 expression mediates TMZ resistance and promotes the progression of glioma},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2025},
doi = {10.1007/s00280-025-04807-3}
}
EUVIMED